For 300 million people, Rare Disease Day is every day

“Orphan diseases”. That’s how rare diseases are sometimes described – a stark reflection of how little attention they have historically received in research and healthcare. And yet, around 300 million people worldwide are living with one. 

For the people living with rare diseases and their loved ones, “rare” isn’t rare at all. It’s a daily reality. It’s years of unanswered questions, navigating complicated care pathways and becoming the expert in your own condition – not by choice, but out of necessity.
For the clinicians supporting people living with rare diseases, it’s complexity, uncertainty and constant learning.
For industry and healthcare systems, it’s a test: how well can innovation be translated into access, education, clearer care pathways and, ultimately, better quality of life?
 

A problem shared is a problem halved 

While individual rare diseases may affect small populations, the challenges surrounding them are often collective. Across the rare disease landscape, we continually see: 

• Diagnostic delay, misdiagnosis, and fragmented pathways 
• Significant unmet need 
• Rapid scientific innovation – accompanied by increasing complexity 
• Rising expectations around experience, access and communication 

Awareness days matter, but they’re not the same as sustained commitment. And innovation on paper doesn’t automatically translate into better experiences in practice. It’s not just about what treatments are coming next, but about how patients and clinicians experience the pathway around them – from first symptom to diagnosis, shared decision making, access to therapy and long-term care. For the teams working behind the scenes in rare disease, this isn’t easy. Budgets are tight and rare disease communities can be understandably cautious; gaining their trust takes time and commitment. When paired with expectations for launch success, teams carry enormous pressure and potential at the same time. It’s hopeful and hard; exhilarating and exasperating all at once. 

Awareness isn’t the same as action 

At Inizio Engage XD, we believe that rare diseases demand more than scientific advancement. Our PX+CX team believe that innovation only makes a difference when it’s shaped around the real experiences of patients, loved ones and clinicians. That means involving them and listening early enough to influence outcomes. It means building the kind of relationships that make authentic and mutually beneficial conversations happen in the first place. And doing it again and again, at each stage of the journey, to make sure we’ve got it right. It means challenging our assumptions and taking the time to fully understand what it feels like to navigate a rare disease diagnosis, as a patient, a loved one or a clinician managing uncertainty. When we genuinely understand the lived experience, we can design communications and engagement that actually support rare disease communities – we do it with them, not for them.  

Over the coming weeks, we’ll be spotlighting some specific rare diseases where we’re seeing momentum, but persistent experience gaps. We’ll explore the evolving landscape, the realities of patient burden, and why experience, for both patients and clinicians, matters just as much as innovation. 

Because, while rare diseases may be individually uncommon, the need for better patient and clinician experiences is widespread. In rare disease, leadership isn’t defined by how loudly we show up on awareness days; it’s defined by what we do in between them year-round. 

If you’re working in rare disease and thinking about how innovation can be translated into better patient and clinician experiences, we’d love to continue the conversation with you.